Vox Markets Logo

Neil Clark of Destiny Pharma: Our number one target is a deal on XF-73 this year

13:09, 13th April 2023
AudioBoom | https://audioboom.com/posts/8280823-neil-clark-of-destiny-pharma-our-number-one-target-is-a-deal-on-xf-73-this-year

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Neil Clark, CEO & Shaun Claydon, CFO of Destiny Pharma Follow | DEST discuss their final results & post period highlights, which included a deal on their lead asset, NTCD-M3, worth up to $570m plus royalties. Neil also points out that the number one target for the company this year is landing a deal on their second late stage asset, XF-73.

Highlights

- Exclusive North American partnering deal worth up to $570m plus royalties secured for NTCD-M3

- Phase 3 development plans finalised for XF-73 nasal following scientific advice from FDA and EMA

- XF-73 dermal commenced clinically enabling safety study sponsored by US Government's NIAID

- New XF research projects initiated in cystic fibrosis and oral mucositis

- Leadership strengthened with appointment of Chief Medical Officer and two Non-Executive Directors

- Balance sheet strengthened through £7.3 million fundraise post period end

To read the full RNS click here

TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles
Watchlist